Latest edition: 04 April 2025
Latest edition: 04 April 2025
Government drug sale clawbacks must be eased for pharma innovation to meet its 10-year plan, say industry representatives.
Streeting said his ten-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.
DHTs are poised to help bolster the density of outcome data in clinical trials involving Parkinson鈥檚 disease.
Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant epilepsy.
Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing their ability to infiltrate solid tumours.
If preclinical findings were translated into clinic, they could shorten CAR-T generation lead time to one day.
Bain Capital鈥檚 Life Sciences team led the funding round, with contributions from new investor Wellington Management.
The therapy is under review in the EU, China and the US for immune thrombocytopenia.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
